physioprotease logo

A Major Breakthrough in Enzyme Therapeutics

pHysioProtease® is a unique, proprietary blend of powerful, non-animal derived proteolytic enzymes that has a long history of use in effectively helping to modulate the immune system, manage inflammation, and maintain optimal systemic health.* Research has shown pHysioProtease® delivers up to 52 times more activity in the physiological conditions of the blood and tissue fluid than other protease blends taken between meals for systemic purposes.

The Problem

It is now generally accepted in the healthcare community that an imbalance in the body’s inflammatory response, particularly in the activity of cytokines, can greatly exacerbate existing health problems throughout the body, prolonging healing time which may lead to reoccurrence or chronicity.[1,2]

body system chart

The Solution

pHysioProtease®, either ingested by itself or in combination with synergistic herbs, vitamins, minerals or phytonutrients, has been clinically-proven to encourage a normal response to inflammatory stimuli in all areas of the body.* Studies suggest, in some cases, supplemental proteases can be even more effective than anti-inflammatory or analgesic drugs in relieving the symptoms of inflammation without the many adverse side-effects.[6-10]*

How pHysioProtease® Works

(hover over icons to learn more)

Absorption & A2M Activation

Inflammation Management

Immune Support

Cardiovascular Maintenance

Why pHysioProtease®

By choosing to use proteases that work best in the blood and tissue fluid, despite the additional cost, pHysioProtease® remains the most effective systemic protease blend available for modulating the inflammatory response and supporting immune and cardiovascular functions.

  1. Kaplin MD LJ. Systemic Inflammatory Response Syndrome. emedicine.medscape.com/article/168943.
  2. Alexandraki K. et al. Inflammation process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci. 2006; 1084:89-117.
  3. Guyton AC, Hall JE. Resistance of the body to infection: I. Leukocytes, granulocytes, the monocyte-macrophage system, and inflammation. In: Textbook of Medical Physiology. Philadelphia, Pa; W.B. Saunders Company; 1996:439-442.
  4. Anft M. Understanding Inflammation. Johns Hopkins Health Review. Spring/Summer 2016. Vol 3 Issue 1.
  5. Taddei S. et al. Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto’s thyroiditis. J Clin Endocrinol Metab. 2006; 91(12):5076-82.
  6. Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S3.
  7. Muhammad ZA, Ahmad T. Therapeutic uses of pineapple-extracted bromelain in surgical care – A review. J Pak Med Assoc. 2017 Jan;67(1):121-125.
  8. Akhtar NM, Naseer R, Farooqi AZ, Aziz W, Nazir M. Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee: a double-blind prospective randomized study. Clin Rheumatol. 2004;23(5):410-415.
  9. WittenBorg A et al. Comparative epidemiological study in patients with rheumatic diseases illustrated in a example of a treatment with non-steroidal anti-inflammatory drugs versus an oral enzyme combination preparation. Arzneimittelforschung. 2000; 50(8):728-38.
  10. Kleine MW, Stauder GM, Beese EW. The intestinal absorption of orally administered hydrolytic enzymes and their effects in the treatment of acute herpes zoster as compared with those of oral acyclovir therapy. Phytomedicine. 1995;2(1):7-15.
  11. Varayil MD JE, MD; Bauer MD BA, Hurt MD, PhD RT. Over-the-Counter Enzyme Supplements: What a Clinician Needs to Know. Mayo Clin Proc. September 2014; 89(9):1307-1312.
  12. Kolac C., Streichhan P., Lehr CM. Oral bioavailability of proteolytic enzymes. European Journal of Pharmaceutics and Biopharmaceutics. 1996, vol. 42, no4, pp. 222-232.
  13. Ambrus JL, et al.: Absorption of exogenous and endogenous proteolytic enzymes. Clin Pharmacol Therap 1967;8:362-8.
  14. Castell, J.V.; Friedrich, G.; Kuhn, C.S.; Poppe, G.E. “Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake”. Am J Physiol 1997; 273: G139-G146.
  15. Nouza K, Wald M. Systemic enzyme therapy: problems of resorption of enzyme macromolecules. Cas Lek Cesk 1995; 134 (19):615-9.
  16. Borth W Alpha 2-macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J. 1992 Dec;6(15):3345-53.
  17. Garzone, PD. Pharmacokinetic and Pharmacodynamic Considerations in the Development of Biotechnology Products and Large Molecules. Principles of Clinical Pharmacology 2nd ed.: 479-500.
  18. Nouza K. Outlooks of systemic enzymes therapy in rheumatoid arthritis and other immunopathological diseases. Acta Univ Carol [Med] (Praha). 1994;40(1-4):101-4.
  19. Larsson, L.J.; Frisch, E.P.; Torneke, K.; Lindblom, T. & Bjork, I. “Properties of the complex between alpha 2-macroglobulin and brinase, a proteinase from Aspergillus oryzae with thrombolytic effect”. Thromb Res 1988; 49: 55-68.
  20. Houston DB, Greaves LS, Andrews LD, Collier AW. Composition and Method for Treating Disease by Increasing Activated Alpha-2-Macroglobulin in the Blood and Extravascular Tissue. US patent 6,413,512. 1999.
  21. LaMarre J et al. Cytokine binding and clearance properties of proteinase-activated alpha- 2-macroglobulins. Lab Invest. 1991;65(1):3-14.
  22. Rehman AAAhsan HKhan FH. Alpha-2-Macroglobulin: a physiological guardian. J Cell Physiol.2013 Aug;228(8):1665-75.
  23. Eming, SA, Krieg T, Davidson JM. Inflammation in Wound Repair: Molecular and Cellular Mechanisms. Journal of Investigative Dermatology. March 2007. 127(3):514-525.
  24. van Gool J , van Vugt H, de Bont E. Alpha 2-macroglobulin and fibrinogen modulate inflammatory edema in man. Inflammation. 1990 Jun;14(3):275-83.
  25. Rathnavelu V, al. Potential role of bromelain in clinical and therapeutic applications. Biomed Rep. 2016 Sep; 5(3): 283–288.
  26. Brown SA, Coimbra M, Coberly DM, Chao JJ, Rohrich RJ. Oral Nutritional Supplementation Accelerates Skin Wound Healing: A Randomized, Placebo-Controlled, Double-Arm, Crossover Study. Plastic & Reconstructive Surgery. July 2004. 114(1):237-244.
  27. Kerkhoffs Gm et al. A double blind, randomised, parallel group study on the efficacy and safety of treating acute lateral ankle sprain with oral hydrolytic Br J Sports Med. 2004 Aug; 38(4) :431-5.
  28. Klein G, Kullich W. Reducing pain by oral enzyme therapy in rheumatic diseases. Wien Med Wochenschr. 1999;149:57780.
  29. Forrester JV,  Wilkinson PC, Lackie Effect of modified alpha 2 macroglobulin on leucocyte locomotion and chemotaxis. Immunology. 1983 Oct; 50(2): 251–259.
  30. Fitzhugh DJ1, Shan S, Dewhirst MW, Hale LP. “Bromelain treatment decreases neutrophil migration to sites of inflammation.” Clin Immunol. 2008 Jul;128(1):66-74.
  31. Hale LP, Greer PK, Sempowski GD. Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. Clin Immunol. 2002;104:183–190. 
  32. Misra UKSharma TPizzo SV. Ligation of cell surface-associated glucose-regulated protein 78 by receptor-recognized forms of alpha 2-macroglobulin: activation of p21-activated protein kinase-2-dependent signaling in murine peritoneal macrophages. J Immunol.2005 Aug 15;175(4):2525-33.
  33. Stauder G. Pharmacological effects of oral enzyme combinations. Cas Lek Cesk. 1995 Oct 4;134(19):620-4.
  34. Steffen CMenzel J. Enzyme breakdown of immune complexes. Z Rheumatol.1983 Sep-Oct;42(5):249-55.
  35. Nakazawa M. et al. Proteolytic enzyme treatment reduces glomerular immune deposits and proteinuria in passive Heymann nephritis. J Exp Med. 1986;164(6):1973-87.
  36. Gesualdo L. et al. Enzymolysis of glomerular immune deposits in vivo with dextranase/protease ameliorates proteinuria, hematuria and mesangial proliferation in murine experimental IgA nephropathy. J Clin Invest. 1990;80:715-22.
  37. Steffen C et al.: Enzyme therapy in comparison with immune complex determinations in chronic polyarteritis. Rheumatologie 1985;44:51-6.
  38. Stauder G et al. The use of hydrolytic enzymes as adjuvant therapy in AIDS/ARC/LAS patients. Biomed Pharmacother. 1988;42(1):31-4.
  39. Wyatt AR et. al. Protease-activated alpha-2-macroglobulin can inhibit amyloid formation via two distinct mechanisms. FEBS Lett. 2013 Mar 1; 587(5): 398–403.
  40. French K, Yerbury JJ, Wilson MR. Protease activation of alpha2-macroglobulin modulates a chaperonelike action with broad specificity. Biochemistry. 2008 Jan 29;47(4):1176-85.
  41. Lauer DReichenbach ABirkenmeier G. Alpha 2-macroglobulin-mediated degradation of amyloid beta 1–42: a mechanism to enhance amyloid beta catabolism. Exp Neurol.2001 Feb;167(2):385-92.
  42. Beuth J. “Proteolytic enzyme therapy in evidence-based complementary oncology: fact or fiction?” Integr Cancer Ther. 2008 Dec;7(4):311-6.
  43. Popiela T et al. Influence of a complementary treatment with oral enzymes on patients with colorectal cancers-an epidemiological retrolective cohort study. Cancer Chemother Pharmacol. 2001;47:S55-63.
  44. Leipner J, Saller R: Systemic enzyme therapy in oncology: effect and mode of action. Drugs. 2000;59:769-80.
  45. Arazi A1, Neumann AU. “Modeling immune complex-mediated autoimmune inflammation.” J Theor Biol. 2010 Dec 7;267(3):426-36.
  46. Nouza K. Systemic enzyme therapy in diseases of the vascular system. Bratisl Lek Listy. 1995 Oct;96(10):566-9.
  47. Pavan R, Jain S, Shraddha, Kumar A. Properties and Therapeutic Application of Bromelain: A Review. Biotechnology Research International. 2012;2012:976203.
  48. Ley CM et al. A review of the use of bromelain in cardiovascular diseases. J of Chinese Integrative Medicine. July 2011. 9(7):702-709.
  49. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application: an update. J Ethnopharmacol. 1988;22(2):191-203.
  50. Food Chemical Codex, 12th edition.
Close Menu